cannabidiol carboxylic acid | 1244-58-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cannabidiol carboxylic acid
• 英文别名: cannabidiolic acid；CBDA；Cannabidiol-saeure；Cannabidiolsaeure；2,4-dihydroxy-3-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylbenzoic acid
• CAS: 1244-58-2；19206-65-6
• 化学式: C₂₂H₃₀O₄
• 分子量: 358.478
• InChiKey: WVOLTBSCXRRQFR-BHWOMJMDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• POLYFUNCTIONAL CANNABINOIDS
  申请人：Axim Biotechnologies, Inc.

  公开号：US20210332004A1

  公开（公告）日：2021-10-28

  This invention discloses cannabinoids linked with polyethylene glycol chains. The cannabinoid-polyethylene glycol chain molecules have one, two, or more cannabinoids linked with one, two, or more polyethylene glycol chains. Each cannabinoid-polyethylene glycol chain molecule may have one kind of cannabinoid or multiple kinds of cannabinoid. Methods to make these cannabinoid-polyethylene glycol linked chains are disclosed.

  这项发明揭示了与聚乙二醇链相连的大麻素。大麻素-聚乙二醇链分子具有一个、两个或更多个大麻素与一个、两个或更多个聚乙二醇链相连。每个大麻素-聚乙二醇链分子可能具有一种大麻素或多种大麻素。揭示了制造这些大麻素-聚乙二醇链的方法。
• [EN] CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS D'ESTER D'ACIDE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：EPM GROUP INC

  公开号：WO2020186010A1

  公开（公告）日：2020-09-17

  The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a cannabidiolic acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

  本公开提供了包括大麻酸酯化合物在内或与一个或多个额外的大麻化合物结合的药物组合物。在一些实施例中，大麻酸酯化合物是大麻二酚酸酯。还提供了大麻酸酯化合物和药物组合物在多种治疗应用中的使用，包括使用大麻酸酯化合物和一个或多个额外治疗剂的联合疗法。
• [EN] CANNABIDIOLIC ACID ESTERS FOR TREATING MUSCULAR DYSTROPHY<br/>[FR] ESTERS D'ACIDE CANNABIDIOLIQUE POUR LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE
  申请人：EPM GROUP INC

  公开号：WO2021137224A1

  公开（公告）日：2021-07-08

  The present invention provides compositions and methods for treating muscular dystrophy. In particular, the present invention provides pharmaceutical compositions and formulations comprising a cannabidiolic acid (CBDA) ester alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating muscular dystrophy.

  本发明提供了用于治疗肌肉萎缩症的组合物和方法。具体而言，本发明提供了包含大麻二酸（CBDA）酯或与一个或多个额外的大麻素化合物结合的药物组合物和配方，以及适用于治疗肌肉萎缩症的药用载体、赋形剂或稀释剂。
• FOOD AND BEVERAGE COMPOSITIONS INFUSED WITH LIPOPHILIC ACTIVE AGENTS AND METHODS OF USE THEREOF
  申请人：Poviva Corp.

  公开号：EP3858364A1

  公开（公告）日：2021-08-04

  Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

  本文所述方面涉及注入亲脂性活性剂的食品和饮料组合物以及用于治疗各种疾病的方法。更具体地说，本文所述方面涉及注入亲脂性活性剂（如大麻素、尼古丁、非甾体抗炎药（NSAIDs）和维生素）的食品和饮料组合物，该组合物可提高亲脂性活性剂在受试者体内的生物利用率，并可掩盖亲脂性活性剂的难闻味道。
• Use of cannabidiol in the treatment of epilepsy
  申请人：GW Pharma Limited

  公开号：US10765643B2

  公开（公告）日：2020-09-08

  The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

  本公开涉及使用大麻二酚（CBD）治疗与艾卡迪综合征相关的癫痫发作。在一个实施方案中，与艾卡迪综合征相关的癫痫发作是抽搐性癫痫发作；伴有损伤或婴儿痉挛的局灶性癫痫发作。本公开进一步涉及 CBD 与一种或多种抗癫痫药物 (AED) 的联合使用。